Show simple item record

dc.contributor.authorAttard, G
dc.contributor.authorAntonarakis, ES
dc.date.accessioned2016-11-23T14:41:25Z
dc.date.issued2016-12
dc.identifier.citationNature reviews. Urology, 2016, 13 (12), pp. 697 - 698
dc.identifier.issn1759-4812
dc.identifier.urihttps://repository.icr.ac.uk/handle/internal/267
dc.identifier.eissn1759-4820
dc.identifier.doi10.1038/nrurol.2016.212
dc.formatPrint-Electronic
dc.format.extent697 - 698
dc.languageeng
dc.language.isoeng
dc.subjectHumans
dc.subjectProstatic Neoplasms
dc.subjectPhenylthiohydantoin
dc.subjectAndrostenes
dc.subjectReceptors, Androgen
dc.subjectAntineoplastic Agents
dc.subjectDrug Resistance, Neoplasm
dc.subjectMale
dc.subjectProstatic Neoplasms, Castration-Resistant
dc.titleProstate cancer: AR aberrations and resistance to abiraterone or enzalutamide.
dc.typeJournal Article
rioxxterms.versionofrecord10.1038/nrurol.2016.212
rioxxterms.licenseref.startdate2016-12
rioxxterms.typeJournal Article/Review
dc.relation.isPartOfNature reviews. Urology
pubs.declined2016-11-10T14:09:24.237+0000
pubs.deleted2016-11-10T14:09:24.237+0000
pubs.issue12
pubs.notesNot known
pubs.organisational-group/ICR
pubs.organisational-group/ICR/Primary Group
pubs.organisational-group/ICR/Primary Group/ICR Divisions
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Molecular Pathology
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Molecular Pathology/Treatment Resistance
pubs.organisational-group/ICR
pubs.organisational-group/ICR/Primary Group
pubs.organisational-group/ICR/Primary Group/ICR Divisions
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Molecular Pathology
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Molecular Pathology/Treatment Resistance
pubs.publication-statusPublished
pubs.volume13
pubs.embargo.termsNot known
icr.researchteamTreatment Resistanceen_US
dc.contributor.icrauthorAttard, Gerhardt


Files in this item

Thumbnail

This item appears in the following collection(s)

Show simple item record